Landmark Agreement for Peptide Manufacturing
Vector Science & Therapeutics Corp. (TSXV: PAIN) announced an exclusive licensing and manufacturing agreement with LyoGenesis Plus, a cGMP lyophilization and manufacturing partner based in Mequon, Wisconsin. Under the agreement, Vector licenses its proprietary biomechanical peptide delivery platform to LyoGenesis in exchange for exclusive, long-term manufacturing rights covering Vector’s proprietary peptide portfolio, which will be sold directly to physicians and clinics.
This new agreement supersedes and renders null Vector’s previously announced option to invest in LyoGenesis Plus, first disclosed on May 13, 2026. The agreement replaces that option with a direct commercial arrangement: a technology license to LyoGenesis in exchange for exclusive manufacturing rights of Vector’s proprietary peptides.
Technology and Quality Standards
Vector’s biomechanical delivery platform incorporates nanoscale carrier technology to enable targeted delivery of peptides directly to specific tissue sites, where the device releases the peptide precisely where needed. This targeted-release mechanism differentiates Vector’s peptide portfolio from conventional peptide therapeutics, giving Vector a suite of patent-protected peptides and a competitive advantage in the peptide therapeutics space.
Unlike research-grade material sold in the unregulated grey market, which is often manufactured without cGMP controls and legally required to be labeled “not for human use,” every peptide in Vector’s portfolio will be manufactured at LyoGenesis’ cGMP facility and tested for potency, purity, endotoxin levels, heavy metals, and sterility prior to release, meeting pharmaceutical-grade quality standards.
Production Capacity and Margins
LyoGenesis will develop Vector’s platform for commercial use, with all Vector peptides formulated at its Mequon, Wisconsin facility. The facility features onsite analytical capabilities to test potency, purity, endotoxin levels, heavy metals, and sterility, ensuring every batch meets rigorous quality standards before release. Depending on demand, Vector and LyoGenesis estimate they will be able to scale production to satisfy up to 800,000 vials per month with gross margins of up to 60-80% per vial for pharma-grade, cGMP-manufactured product.
Proprietary Peptide Portfolio
Vector’s proprietary peptide portfolio, which will be manufactured under the new agreement and distributed exclusively through physician and clinical channels, includes: BPC-157, TB-500, PT-141, Sermorelin, CJC-1295, Ipamorelin, MOTS-c, GHK-Cu, DSIP, KPV, Kisspeptin, Epitalon, Dihexa, Semax, LL-37, Pinealon, Selank, SS-31, Melanotan II, Ibutamoren (mesylate), NAD+, Semaglutide, and Tirzepatide.
According to Vector, this agreement secures an exclusive, long-term manufacturing relationship covering its entire proprietary peptide portfolio, which will be sold directly to physicians and clinics, ensuring pharmaceutical-grade quality and supply chain reliability.
